Immuron (IMC.AX) Stock Price

Immuron Price

ASX·CLOSED
0.04AUD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 2.2% per year over the past 19 years to 7.29 M AUD. Immuron's net margin stands at -71.6%, up from -5,750.7% several years earlier. The stock trades about 65% above its 52-week low.

Immuron stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Immuron over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immuron stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immuron's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Immuron Stock Price History
DateImmuron Price
7/10/20260.04 AUD
7/9/20260.04 AUD
7/8/20260.04 AUD
7/7/20260.04 AUD
7/6/20260.04 AUD
7/3/20260.04 AUD
7/2/20260.04 AUD
7/1/20260.03 AUD
6/30/20260.03 AUD
6/29/20260.04 AUD
6/26/20260.03 AUD
6/25/20260.04 AUD
6/24/20260.04 AUD
6/23/20260.04 AUD
6/22/20260.03 AUD
6/19/20260.03 AUD
6/18/20260.03 AUD
6/17/20260.03 AUD
6/16/20260.04 AUD
6/15/20260.04 AUD
6/12/20260.03 AUD
6/11/20260.04 AUD
6/10/20260.04 AUD
6/9/20260.04 AUD
6/5/20260.04 AUD
6/4/20260.04 AUD
6/3/20260.04 AUD
6/2/20260.05 AUD
6/1/20260.05 AUD
5/29/20260.04 AUD
5/28/20260.04 AUD
5/27/20260.03 AUD
5/26/20260.03 AUD
5/25/20260.03 AUD
5/22/20260.03 AUD
5/21/20260.03 AUD
5/20/20260.03 AUD
5/19/20260.03 AUD
5/18/20260.03 AUD
5/15/20260.03 AUD
5/14/20260.03 AUD
5/13/20260.03 AUD
5/12/20260.03 AUD
5/11/20260.03 AUD
5/8/20260.03 AUD
5/7/20260.03 AUD
5/6/20260.03 AUD
5/5/20260.03 AUD
5/4/20260.03 AUD
5/1/20260.03 AUD
4/30/20260.03 AUD
4/29/20260.03 AUD
4/28/20260.03 AUD
4/27/20260.03 AUD
4/24/20260.03 AUD
4/23/20260.03 AUD
4/22/20260.03 AUD
4/21/20260.03 AUD
4/20/20260.03 AUD
4/17/20260.04 AUD
4/16/20260.03 AUD
4/15/20260.03 AUD
4/14/20260.03 AUD
4/13/20260.03 AUD
4/10/20260.03 AUD
4/9/20260.03 AUD
4/8/20260.03 AUD
4/7/20260.03 AUD
4/2/20260.03 AUD
4/1/20260.03 AUD
3/31/20260.03 AUD
3/30/20260.03 AUD
3/27/20260.03 AUD
3/26/20260.03 AUD
3/25/20260.03 AUD
3/24/20260.03 AUD
3/23/20260.03 AUD
3/20/20260.03 AUD
3/19/20260.03 AUD
3/18/20260.03 AUD
3/17/20260.03 AUD
3/16/20260.03 AUD
3/13/20260.03 AUD
3/12/20260.03 AUD
3/11/20260.03 AUD
3/10/20260.03 AUD
3/9/20260.03 AUD
3/6/20260.03 AUD
3/5/20260.03 AUD
3/4/20260.03 AUD
3/3/20260.03 AUD
3/2/20260.03 AUD
2/27/20260.03 AUD
2/26/20260.03 AUD
2/25/20260.03 AUD
2/24/20260.03 AUD
2/23/20260.03 AUD
2/20/20260.03 AUD
2/19/20260.03 AUD
2/18/20260.03 AUD
2/17/20260.03 AUD
2/16/20260.03 AUD
2/13/20260.03 AUD
2/12/20260.03 AUD
2/11/20260.03 AUD
2/10/20260.03 AUD
2/9/20260.03 AUD
2/6/20260.03 AUD
2/5/20260.03 AUD
2/4/20260.03 AUD
2/3/20260.03 AUD
2/2/20260.03 AUD
1/30/20260.04 AUD
1/29/20260.04 AUD
1/28/20260.04 AUD
1/27/20260.04 AUD
1/23/20260.04 AUD
1/22/20260.04 AUD
1/21/20260.04 AUD
1/20/20260.04 AUD
1/19/20260.04 AUD
1/16/20260.04 AUD
1/15/20260.04 AUD
1/14/20260.04 AUD
1/13/20260.04 AUD
1/12/20260.03 AUD
1/9/20260.04 AUD
1/8/20260.04 AUD
1/7/20260.04 AUD
1/6/20260.04 AUD
1/5/20260.04 AUD
1/2/20260.04 AUD
12/31/20250.04 AUD
12/30/20250.04 AUD
12/29/20250.04 AUD
12/24/20250.04 AUD
12/23/20250.04 AUD
12/22/20250.04 AUD
12/19/20250.04 AUD
12/18/20250.04 AUD
12/17/20250.04 AUD
12/16/20250.04 AUD
12/15/20250.04 AUD
12/12/20250.04 AUD
12/11/20250.04 AUD
12/10/20250.04 AUD
12/9/20250.06 AUD
12/8/20250.06 AUD
12/5/20250.06 AUD
12/4/20250.06 AUD
12/3/20250.07 AUD
12/2/20250.07 AUD
12/1/20250.07 AUD
11/28/20250.06 AUD
11/27/20250.06 AUD
11/26/20250.07 AUD
11/25/20250.07 AUD
11/24/20250.06 AUD
11/21/20250.06 AUD
11/20/20250.06 AUD
11/19/20250.06 AUD
11/18/20250.06 AUD
11/17/20250.06 AUD
11/14/20250.06 AUD
11/13/20250.07 AUD
11/12/20250.07 AUD
11/11/20250.06 AUD
11/10/20250.06 AUD
11/7/20250.07 AUD
11/6/20250.07 AUD
11/5/20250.09 AUD
11/4/20250.08 AUD
11/3/20250.08 AUD
10/31/20250.08 AUD
10/30/20250.09 AUD
10/29/20250.09 AUD
10/28/20250.09 AUD
10/27/20250.09 AUD
10/24/20250.09 AUD
10/23/20250.08 AUD
10/22/20250.08 AUD
10/21/20250.08 AUD
10/20/20250.09 AUD
10/17/20250.08 AUD
10/16/20250.08 AUD
10/15/20250.08 AUD
10/14/20250.08 AUD
10/13/20250.08 AUD
10/10/20250.09 AUD
10/9/20250.09 AUD
10/8/20250.09 AUD
10/7/20250.09 AUD
10/6/20250.09 AUD
10/3/20250.09 AUD
10/2/20250.09 AUD
10/1/20250.08 AUD
9/30/20250.08 AUD
9/29/20250.08 AUD
9/26/20250.08 AUD
9/25/20250.08 AUD
9/24/20250.08 AUD
9/23/20250.08 AUD
9/22/20250.08 AUD
9/19/20250.08 AUD
9/18/20250.08 AUD
9/17/20250.07 AUD
9/16/20250.07 AUD
9/15/20250.07 AUD
9/12/20250.07 AUD
9/11/20250.07 AUD
9/10/20250.07 AUD
9/9/20250.07 AUD
9/8/20250.07 AUD
9/5/20250.07 AUD
9/4/20250.07 AUD
9/3/20250.07 AUD
9/2/20250.07 AUD
9/1/20250.07 AUD
8/29/20250.07 AUD
8/28/20250.07 AUD
8/27/20250.07 AUD
8/26/20250.07 AUD
8/25/20250.07 AUD
8/22/20250.07 AUD
8/21/20250.07 AUD
8/20/20250.07 AUD
8/19/20250.07 AUD
8/18/20250.07 AUD
8/15/20250.07 AUD
8/14/20250.07 AUD
8/13/20250.07 AUD
8/12/20250.07 AUD
8/11/20250.07 AUD
8/8/20250.07 AUD
8/7/20250.07 AUD
8/6/20250.07 AUD
8/5/20250.07 AUD
8/4/20250.07 AUD
8/1/20250.06 AUD
7/31/20250.06 AUD
7/30/20250.07 AUD
7/29/20250.06 AUD
7/28/20250.07 AUD
7/25/20250.08 AUD
7/24/20250.08 AUD
7/23/20250.07 AUD
7/22/20250.07 AUD
7/21/20250.07 AUD
7/18/20250.08 AUD
7/17/20250.07 AUD
7/16/20250.06 AUD
7/15/20250.06 AUD
7/14/20250.06 AUD
Access this data via the Eulerpool API
Get Free API Key

Immuron Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
3.69 M AUD
-2.83 M AUD
-3.01 M AUD
Jan 1, 2019
2.39 M AUD
-4.69 M AUD
-4.66 M AUD
Jan 1, 2020
2.52 M AUD
-3.07 M AUD
-2.93 M AUD
Jan 1, 2021
145,800.00 AUD
-7.20 M AUD
-8.38 M AUD
Jan 1, 2022
765,200.00 AUD
-3.12 M AUD
-2.85 M AUD
Jan 1, 2023
1.80 M AUD
-3.44 M AUD
-3.79 M AUD
Jan 1, 2024
4.90 M AUD
-5.24 M AUD
-6.94 M AUD
Jan 1, 2025
7.29 M AUD
-5.36 M AUD
-5.22 M AUD

Immuron Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 6:39 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
––––1.001.003.002.003.002.002.00––1.004.007.00
––––––200.00-33.3350.00-33.33––––300.0075.00
––––400.00400.00100.00100.00100.0050.0050.00––100.0075.0057.14
4.004.004.004.004.004.003.002.003.001.001.004.004.001.003.004.00
-1.00-2.00-2.00-3.00-2.00-3.00-5.00-6.00-3.00-4.00-2.00-8.00-2.00-3.00-6.00-5.00
-50.00100.00–50.00-33.3350.0066.6720.00-50.0033.33-50.00300.00-75.0050.00100.00-16.67
10.6212.7513.9214.3342.2275.5876.44105.87133.66144.74176.39221.06227.58227.80227.86230.80
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Immuron generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immuron retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immuron's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Immuron has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immuron's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Immuron stock margins

The Immuron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immuron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immuron.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
88.66 %
-76.58 %
-81.52 %
Jan 1, 2019
72.05 %
-196.65 %
-195.04 %
Jan 1, 2020
72.65 %
-121.96 %
-116.22 %
Jan 1, 2021
64.95 %
-4,937.72 %
-5,750.69 %
Jan 1, 2022
68.41 %
-407.40 %
-373.01 %
Jan 1, 2023
96.42 %
-190.44 %
-209.81 %
Jan 1, 2024
68.06 %
-106.95 %
-141.49 %
Jan 1, 2025
65.39 %
-73.51 %
-71.58 %

Immuron Stock Revenue, EBIT, Earnings per Share

The Immuron earnings per share therefore indicates how much revenue Immuron has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.03 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2019
0.02 AUD
-0.03 AUD
-0.03 AUD
Jan 1, 2020
0.01 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2021
0.00 AUD
-0.03 AUD
-0.04 AUD
Jan 1, 2022
0.00 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2023
0.01 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2024
0.02 AUD
-0.02 AUD
-0.03 AUD
Jan 1, 2025
0.03 AUD
-0.02 AUD
-0.02 AUD

Immuron business model & stock analysis

Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future.

Immuron SWOT Analysis

Strengths

Immuron Ltd has several strengths that give it a competitive advantage in the market. Firstly, the company has a strong and experienced management team with a track record of success in the biotech industry. This provides a solid foundation for decision-making and strategy execution.

Additionally, Immuron Ltd has developed a unique platform technology that allows for the creation of novel and effective therapeutic products. This technology has the potential to revolutionize the treatment of certain diseases and provides the company with a distinct market edge.

The company also benefits from a diverse product portfolio, with multiple candidates in various stages of development. This diversity mitigates the risk associated with relying solely on one product and provides multiple revenue streams for the company.

Weaknesses

Despite its strengths, Immuron Ltd also faces certain weaknesses that need to be addressed. One key weakness is the company's limited financial resources. This constraint may hinder the company's ability to fully exploit its technology and commercialize its products.

Another weakness lies in the company's heavy dependence on its research and development pipeline. Delays or failures in the pipeline could significantly impact Immuron Ltd's revenue generation and overall growth prospects.

Opportunities

Immuron Ltd operates in an industry with immense growth potential. The rising prevalence of various diseases, coupled with increasing healthcare expenditure, presents significant opportunities for the company to expand its market reach and capture a larger share.

Furthermore, advancements in technology and the growing trend towards personalized medicine open doors for Immuron Ltd to develop targeted therapies tailored to individual patients, which can enhance treatment efficacy and drive demand for its products.

Threats

Immuron Ltd operates in a highly competitive landscape, with numerous biotech companies vying for market share. This intensifying competition poses a threat to the company's market position and profitability.

Additionally, regulatory uncertainty and stringent approval processes for new drugs and treatments can pose significant challenges for Immuron Ltd's product development and commercialization efforts.

Immuron Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Immuron historical P/E ratio, EBIT multiple, and P/S ratio

Immuron annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Immuron shares outstanding

The number of shares of Immuron was 230.8 M in 2025. This indicates how many shares Immuron is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
133.66 M Stocks
Jan 1, 2019
144.74 M Stocks
Jan 1, 2020
176.39 M Stocks
Jan 1, 2021
221.06 M Stocks
Jan 1, 2022
227.58 M Stocks
Jan 1, 2023
227.80 M Stocks
Jan 1, 2024
227.86 M Stocks
Jan 1, 2025
230.80 M Stocks

Immuron stock splits

In Immuron's history, there have been no stock splits.
Price targets and forecasts for Immuron are not yet available.

Immuron shareholder structure

% Name
2.38306%
Authentics Australia Pty. Ltd.
Authentics Australia Pty. Ltd.
1.66672%
Grandlodge Pty. Ltd.
Grandlodge Pty. Ltd.
1.29985%
Hancock (Russell Kay)
Hancock (Russell Kay)
1.08093%
Anastasiou (Stephen)
Anastasiou (Stephen)
1.00291%
Texas Woods Pty Ltd
Texas Woods Pty Ltd
0.90989%
Yu (Lizhong)
Yu (Lizhong)

Immuron Executives and Management Board

JK

Dr. Jerry Kanellos

(60)

Chief Operating Officer

Compensation392,726.00 AUD
DP

Mr. Daniel Pollock

(61)

Non-Executive Independent Director

Compensation94,875.00 AUD
PS

Prof. Ravi Savarirayan

(55)

Non-Executive Independent Director

Compensation65,001.00 AUD
SL

Mr. Steven Lydeamore

(54)

Chief Executive Officer

Compensation32,784.00 AUD
PB

Mr. Paul Brennan

(61)

Non-Executive Independent Chairman of the Board

Compensation22,459.00 AUD

Immuron Supply Chain

Immuron Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#Name1M3M6M1Y2YTrend
1
Synlait Milk
Supplier
0.57
0.46
0.18
0.52
—
2
HSBC Holdings
Supplier
0.14
-0.47
-0.02
-0.53
—
3
Thermo Fisher Scientific
Supplier
0.09
0.38
0
-0.59
—

Frequently asked questions about Immuron

The business model of Immuron Ltd revolves around developing and commercializing oral immunotherapy products for the treatment of various gut-mediated diseases. The company utilizes its proprietary technology platform to develop and manufacture these therapeutic products, which aim to restore and maintain a healthy balance of gut microflora. Through targeted research and clinical studies, Immuron aims to address unmet medical needs in areas such as diarrhea-predominant irritable bowel syndrome, nonalcoholic steatohepatitis, and liver diseases. By harnessing the potential of its therapeutic candidates, Immuron Ltd strives to improve the health and well-being of patients worldwide.

All fundamentals and in-depth analysis of Immuron

Our stock analysis for Immuron stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuron. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Immuron Stock
Immuron Revenue→
Immuron Stock
Immuron Net Income→
Immuron Stock
Immuron P/E→
Immuron Stock
Immuron P/S→
Immuron Stock
Immuron EBIT→
Immuron Stock
Immuron Dividend→
Immuron Stock
Immuron Directors Dealings→
Immuron Stock
Immuron Stocks→
Immuron Stock
Immuron Market capitalization→
Immuron Stock
Immuron Debt→
Immuron Stock
Immuron Liabilities→
Immuron Stock
Immuron Equity→
Immuron Stock
Immuron AAQS→
Immuron Stock
Immuron Employees→
Immuron Stock
Immuron ROE→
Immuron Stock
Immuron ROA→
Immuron Stock
Immuron ROCE→
Immuron Stock
Immuron News→
Immuron Stock
Immuron Analyst Price Targets→

Health Stocks

Immuron Ltd ADRImmunovia AB (publ)ImmutepImmunovantImmutep Ltd ADRImmunotech LaboratoriesImpediMedImmunotech BiopharmImplanetImmunomeImprove Medical Instruments CoImmunocore HoldingsAll Stocks A–Z →